These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28562096)

  • 21. Targeting angiogenesis in endometrial cancer - new agents for tailored treatments.
    Papa A; Zaccarelli E; Caruso D; Vici P; Benedetti Panici P; Tomao F
    Expert Opin Investig Drugs; 2016; 25(1):31-49. PubMed ID: 26560489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
    Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
    Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Understanding current therapies in metastatic melanoma].
    Rodríguez R; Parra A; González S; Molgó M; Droppelmann N; Acevedo F; Peña J; Uribe P
    Rev Med Chil; 2016 Nov; 144(11):1448-1458. PubMed ID: 28394962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma.
    Zahoor H; Rini BI
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):431-440. PubMed ID: 27690664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.
    Eggermont AM; Maio M; Robert C
    Semin Oncol; 2015 Jun; 42(3):429-35. PubMed ID: 25965361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.
    O'reilly A; Larkin J
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):647-655. PubMed ID: 28604130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anticancer therapy with angiogenesis inhibitors.
    Ghilardi C; Bani MR; Giavazzi R
    Tumori; 2001; 87(6):S14-6. PubMed ID: 11989610
    [No Abstract]   [Full Text] [Related]  

  • 28. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
    Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
    Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunotherapies and melanoma].
    Routier É; Robert C; Mateus C
    Bull Cancer; 2014 Dec; 101 Suppl 2():S13-24. PubMed ID: 25776763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
    Kakavand H; Wilmott JS; Long GV; Scolyer RA
    Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents.
    Moschos SJ; Odoux C; Land SR; Agarwala S; Friedland D; Volker KM; Sidor C; Wong M; Kirkwood JM
    Melanoma Res; 2007 Jun; 17(3):193-200. PubMed ID: 17505265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of melanoma-associated neoangiogenesis by bevacizumab.
    Jaissle GB; Ulmer A; Henke-Fahle S; Fierlbeck G; Bartz-Schmidt KU; Szurman P
    Arch Dermatol; 2008 Apr; 144(4):525-7. PubMed ID: 18427047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice.
    Silva IP; Long GV
    Curr Opin Oncol; 2017 Nov; 29(6):484-492. PubMed ID: 28914644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunotherapy in the treatment of advanced or metastatic melanoma: nivolumab from phase I studies to approvement by European Medicines Agency].
    Queirolo P; Tanda ET
    Recenti Prog Med; 2015 Dec; 106(12):608-17. PubMed ID: 26780070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiogenesis in melanoma: an update with a focus on current targeted therapies.
    Jour G; Ivan D; Aung PP
    J Clin Pathol; 2016 Jun; 69(6):472-83. PubMed ID: 26865640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer immunology - development of novel anti-cancer therapies.
    Rothschild SI; Thommen DS; Moersig W; Müller P; Zippelius A
    Swiss Med Wkly; 2015; 145():w14066. PubMed ID: 25668078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.
    Minion LE; Tewari KS
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):191-198. PubMed ID: 27748633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer.
    Huang Y; Carbone DP
    Biochim Biophys Acta; 2015 Apr; 1855(2):193-201. PubMed ID: 25598052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Binimetinib for the treatment of NRAS-mutant melanoma.
    Queirolo P; Spagnolo F
    Expert Rev Anticancer Ther; 2017 Nov; 17(11):985-990. PubMed ID: 28851243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).
    Peng FW; Liu DK; Zhang QW; Xu YG; Shi L
    Expert Opin Ther Pat; 2017 Sep; 27(9):987-1004. PubMed ID: 28621580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.